Abstract | GOALS: BACKGROUND: STUDY: RESULTS: Three of 10 subjects had an on-treatment virologic response, although one had a breakthrough with recurrent viremia during treatment and two relapsed after therapy was completed. On treatment responders had significantly higher trough cyclosporine levels at week 4 compared with nonresponders (P = 0.025). Serum creatinine levels remained stable, and no patient developed diabetes. Triglyceride levels increased during treatment. Cyclosporine was dose reduced in two patients for hypertension. CONCLUSIONS: Selected patients with hepatitis C tolerated therapy, including cyclosporine without severe or irreversible toxicity. Despite an association between higher cyclosporine levels and on-treatment response, the combination of cyclosporine and interferon was ineffective in producing a sustained response in previous nonresponder patients.
|
Authors | Scott J Cotler, Mary J Morrissey, Thelma E Wiley, Thomas J Layden, Donald M Jensen |
Journal | Journal of clinical gastroenterology
(J Clin Gastroenterol)
Vol. 36
Issue 4
Pg. 352-5
(Apr 2003)
ISSN: 0192-0790 [Print] United States |
PMID | 12642744
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Interferon Type I
- Interferon-alpha
- Recombinant Proteins
- interferon alfacon-1
- Cyclosporine
|
Topics |
- Adult
- Cyclosporine
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hepatitis C
(diagnosis, drug therapy)
- Humans
- Injections, Subcutaneous
- Interferon Type I
(administration & dosage)
- Interferon-alpha
- Male
- Middle Aged
- Pilot Projects
- Probability
- Recombinant Proteins
- Remission Induction
- Sampling Studies
- Statistics, Nonparametric
- Treatment Failure
- Treatment Outcome
|